JW gains solid tumor technology license through recent acquisition

By Nikita Chaurasia  | Date: 2020-07-21

JW gains solid tumor technology license through recent acquisition

JW Therapeutics, a biotechnology company headquartered in Shanghai, China, has reportedly acquired Syracuse Biopharma (Hong Kong) Ltd., inclusive of a licensing agreement for Eureka Therapeutics’ solid tumor technology and ARTEMIS® antibody TCR for exclusive use in China and ASEAN nations.

Earlier this month, JW Therapeutics collaborated with Acepodia for the commercialization of two of company’s cell therapy candidates for treating solid tumors and hematologic malignancies.

Dr. James Li, Co-Founder and Head of JW Therapeutics, stated that the company is excited to declare the acquisition of Syracuse for strengthening its clinical expertise in solid tumor cancers. Syracuse and Eureka have devised a unique and effective approach for treating solid tumors with their T-cell receptor antibody mimic antibody (TCRm-Ab) and ARTEMIS® technologies. The company is looking to forward to work with them to deliver the next generation of T cell immunotherapies to patients, he added.

On the other side, Founder and CEO of Eureka Therapeutics, Dr. Cheng Liu is equally excited to work with JW Therapeutics for having recognized the value of the propriety ARTEMIS® platform. With the help of JW, the company is looking to leverage the new-found resources to speed up the development of T cell therapies for its battle against solid tumors.

The number of hepatocellular carcinoma (HCC) cases in China is very high and JW is strategically positioned to develop these therapies and increase its accessibility to patients across China, he added.

Founder and President of Eureka Therapeutics, Dr. Cheng Liu, will now be a part of the Board of Directors at JW Therapeutics, while the Chief Business Officer and General Counsel of Eureka, Victor Shum, will take on the role of a Board Observer, claim credible sources.

The terms of the deal have not been disclosed so far.

Sources: https://www.businesswire.com/news/home/20200720005179/en/JW-Therapeutics-Acquires-Syracuse-Biopharma-License-Eureka

https://www.globenewswire.com/news-release/2020/07/14/2061786/0/en/Acepodia-and-JW-Therapeutics-Enter-into-Option-and-License-Agreement-for-Off-the-shelf-NK-Cell-Therapies.html

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More >>

More News By Nikita Chaurasia

L&T Technology Services partners with Qualcomm to amplify 5G adoption

L&T Technology Services partners with Qualcomm to amplify 5G adoption

By Nikita Chaurasia

L&T Technology Services Limited has recently announced that it is teaming up with Qualcomm Technologies, Inc., the world’s leading wireless technology innovator. With the latest collaboration, the firm plans to offer end-to-end solutions...

PNAS, Straive partner to deliver end-to-end content production services

PNAS, Straive partner to deliver end-to-end content production services

By Nikita Chaurasia

Renowned U.S.-based nonprofit and non-governmental organization, NAS (National Academy of Sciences), has reportedly collaborated with Straive, one of the leading technology-driven solutions providers for Content, EdTech, and Data. With this acquis...

Japan pushes innovations in 'deep tech' sector with solar cell technology

Japan pushes innovations in 'deep tech' sector with solar cell technology

By Nikita Chaurasia

Amid the most promising next-generation solar cell technology innovations, Enecoat Technologies, a provider of materials development services in Japan, is reportedly developing perovskite. Following its completion, the Kyoto-located start-up expec...

GIC to acquire majority shares in opulent Sani/Ikos properties

GIC to acquire majority shares in opulent Sani/Ikos properties

By Nikita Chaurasia

Singapore's sovereign wealth fund, GIC has agreed to pay around $2.2 billion to buy a majority stake in Sani/Ikos Group, a Mediterranean luxury resort operator, marking the largest transaction in the European resort market since the Covid-19 pand...

Excelra, Patcore partner to offer enhanced digital insights to customers

Excelra, Patcore partner to offer enhanced digital insights to customers

By Nikita Chaurasia

Excelra, a data and analytics solutions provider, has recently announced its partnership with Patcore, Inc., to provide better access to its analytics products and scientific data for customers in Japan. For the unversed, Excelra is one of the top...